Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9143702 | 0.83 | SMN1; SMN2 (0.63) | SMN1; SMN2POLBMAPTRAB9ANPC1 | |
| SCHEMBL5151678 | 0.83 | GAA (0.64) | SMN1; SMN2POLBMAPTRAB9ANPC1 | |
| SCHEMBL8898674 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2POLBMAPTRAB9ANPC1 | |
| SCHEMBL30014816 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBMAPTRAB9ANPC1 | |
| SCHEMBL13233272 | 0.80 | KMT2A (0.64) | SMN1; SMN2POLBMAPTRAB9ANPC1 | |
| SCHEMBL5100760 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBMAPTRAB9ANPC1 | |
| SCHEMBL7363076 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBMAPTRAB9ANPC1 | |
| SCHEMBL1146057 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBMAPTRAB9ANPC1 | |
| SCHEMBL5650522 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBMAPTRAB9ANPC1 | |
| SCHEMBL6162165 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784293-B1 | SOLUTION AND SOLID-PHASE SYNTHESIS OF BOC-PROTECTED 3-AMINOHYDANTOINS/THIOHYDANTOINS AND 3-AMINODIHYDROURACILS/ DIHYDROTHIOURACILS | THE PROCTER & GAMBLE COMPANY | 2004-08-31 | — | — | US | claimed |
| EP-0937040-B1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2004-07-21 | — | — | EP | claimed |
| EP-0937040-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 1999-08-25 | — | — | EP | claimed |
| WO-1998019998-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 1998-05-14 | — | — | WO | claimed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| CN-100506801-C | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1653970-A4 | GSK-3 INHIBITORS AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| EP-1653970-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2005039485-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2002016318-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2002-02-28 | — | — | WO | disclosed |
| CN-1312807-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2001-09-12 | — | — | CN | disclosed |
| WO-2001027087-A2 | PROCESS FOR MAKING BOC-PROTECTED 3-AMINOHYDANTOINS/THIOHYDANTOINS AND 3-AMINODIHYDROURACILS/DIHYDROTHIOURACILS | THE PROCTER & GAMBLE COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| CN-1236361-A | N-substituted 2-cyanopyrrolidines | NOVARTIS AG (CH) | 1999-11-24 | — | — | CN | disclosed |
| EP-0937040-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998019998-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | SMN1; SMN2 3262/4885POLB 866/4885MAPT 158/4885 |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | SMN1; SMN2 4194/4885POLB 4723/4885MAPT 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.